OXERVATE eye drops show lasting healing in rare eye disease Follow-Up

NCT ID NCT05552261

Completed Disease control Sponsor: Dompé Farmaceutici S.p.A Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 26 times

Summary

This study followed 24 people with stage 1 neurotrophic keratitis, a rare eye condition where the cornea doesn't heal properly, to see if OXERVATE eye drops remain safe and effective over 30 months. Participants had already completed the earlier DEFENDO study. Researchers tracked corneal healing, eye sensitivity, tear function, vision, and quality of life. The goal was to confirm long-term benefits and safety of the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROTROPHIC KERATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cincinnati Eye Institute

Edgewood, Kentucky, 41017, United States
New Vision Institute

San Diego, California, 92037, United States
Scheie Eye Institute

Philadelphia, Pennsylvania, 19104, United States
Tufts Medical Center

Boston, Massachusetts, 02011, United States

Conditions

Explore the condition pages connected to this study.

NEUROTROPHIC KERATITIS